Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$113.16
-0.84-0.74%
At close: -
$113.16
0.000.00%
After Hours: Mar 28, 4:00 PM EDT
Comments
Loading...
Neurocrine Biosciences Analyst Ratings and Price Targets | NASDAQ:NBIX | Benzinga
Neurocrine Biosciences Inc has a consensus price target of $162.83 based on the ratings of 25 analysts. The high is $219 issued by Oppenheimer on August 2, 2024. The low is $114 issued by BMO Capital on October 17, 2024. The 3 most-recent analyst ratings were released by JP Morgan, Morgan Stanley, and HC Wainwright & Co. on March 26, 2025, March 7, 2025, and February 24, 2025, respectively. With an average price target of $173 between JP Morgan, Morgan Stanley, and HC Wainwright & Co., there's an implied 52.88% upside for Neurocrine Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Morgan Stanley
HC Wainwright & Co.
Guggenheim
RBC Capital
1calculated from analyst ratings
Analyst Ratings for Neurocrine Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/26/2025 | Buy Now | 62.6% | JP Morgan | Anupam Rama59% | $183 → $184 | Maintains | Overweight | Get Alert |
| 03/07/2025 | Buy Now | 32.56% | Morgan Stanley | Jeffrey Hung55% | $185 → $150 | Assumes | → Overweight | Get Alert |
| 02/24/2025 | Buy Now | 63.49% | HC Wainwright & Co. | Andrew Fein56% | $185 → $185 | Reiterates | Buy → Buy | Get Alert |
| 02/21/2025 | Buy Now | 63.49% | HC Wainwright & Co. | Andrew Fein56% | $185 → $185 | Reiterates | Buy → Buy | Get Alert |
| 02/10/2025 | Buy Now | 44.04% | Guggenheim | Yatin Suneja48% | $165 → $163 | Maintains | Buy | Get Alert |
| 02/10/2025 | Buy Now | 63.49% | HC Wainwright & Co. | Andrew Fein56% | $190 → $185 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | 30.79% | RBC Capital | Brian Abrahams52% | $154 → $148 | Maintains | Sector Perform | Get Alert |
| 02/07/2025 | Buy Now | 29.9% | Wedbush | Laura Chico47% | $157 → $147 | Maintains | Outperform | Get Alert |
| 02/07/2025 | Buy Now | 44.04% | Canaccord Genuity | Sumant Kulkarni43% | $172 → $163 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | 63.49% | HC Wainwright & Co. | Andrew Fein56% | $190 → $185 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | — | Needham | Ami Fadia61% | — | Reiterates | Hold → Hold | Get Alert |
| 02/07/2025 | Buy Now | 58.18% | B of A Securities | Tazeen Ahmad55% | $184 → $179 | Maintains | Buy | Get Alert |
| 02/04/2025 | Buy Now | 63.49% | Morgan Stanley | Jeffrey Hung55% | $170 → $185 | Maintains | Overweight | Get Alert |
| 01/30/2025 | Buy Now | 55.53% | UBS | Ashwani Verma47% | $162 → $176 | Maintains | Buy | Get Alert |
| 01/08/2025 | Buy Now | 43.16% | UBS | Ashwani Verma47% | $142 → $162 | Maintains | Buy | Get Alert |
| 12/23/2024 | Buy Now | 41.39% | Piper Sandler | David Amsellem71% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 12/23/2024 | Buy Now | 45.81% | Barclays | Carter Gould58% | $160 → $165 | Maintains | Overweight | Get Alert |
| 12/20/2024 | Buy Now | — | Needham | Ami Fadia61% | — | Reiterates | Hold → Hold | Get Alert |
| 12/16/2024 | Buy Now | 30.79% | Wedbush | Laura Chico47% | $148 → $148 | Reiterates | Outperform → Outperform | Get Alert |
| 12/16/2024 | Buy Now | 67.9% | HC Wainwright & Co. | Andrew Fein56% | $190 → $190 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | — | Needham | Ami Fadia61% | — | Reiterates | → Hold | Get Alert |
| 11/01/2024 | Buy Now | 67.9% | HC Wainwright & Co. | Andrew Fein56% | $190 → $190 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | — | Needham | Ami Fadia61% | — | Reiterates | → Hold | Get Alert |
| 10/30/2024 | Buy Now | — | Needham | Ami Fadia61% | — | Reiterates | → Hold | Get Alert |
| 10/29/2024 | Buy Now | — | Needham | Ami Fadia61% | — | Reiterates | → Hold | Get Alert |
| 10/17/2024 | Buy Now | 0.74% | BMO Capital | Evan Seigerman64% | $128 → $114 | Maintains | Market Perform | Get Alert |
| 10/10/2024 | Buy Now | 36.97% | Raymond James | Danielle Brill43% | → $155 | Reinstates | → Outperform | Get Alert |
| 10/08/2024 | Buy Now | 17.53% | RBC Capital | Brian Abrahams52% | $133 → $133 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 10/04/2024 | Buy Now | 17.53% | RBC Capital | Brian Abrahams52% | $136 → $133 | Maintains | Sector Perform | Get Alert |
| 09/16/2024 | Buy Now | 36.97% | Cantor Fitzgerald | Charles Duncan72% | $155 → $155 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | 41.39% | Barclays | Carter Gould58% | $180 → $160 | Maintains | Overweight | Get Alert |
| 08/29/2024 | Buy Now | 36.97% | Cantor Fitzgerald | Charles Duncan72% | $170 → $155 | Maintains | Overweight | Get Alert |
| 08/29/2024 | Buy Now | 13.11% | BMO Capital | Evan Seigerman64% | $142 → $128 | Maintains | Market Perform | Get Alert |
| 08/29/2024 | Buy Now | 40.51% | Piper Sandler | David Amsellem71% | $131 → $159 | Upgrade | Neutral → Overweight | Get Alert |
| 08/29/2024 | Buy Now | 20.18% | RBC Capital | Brian Abrahams52% | $143 → $136 | Maintains | Sector Perform | Get Alert |
| 08/29/2024 | Buy Now | 67.9% | HC Wainwright & Co. | Andrew Fein56% | $190 → $190 | Reiterates | Buy → Buy | Get Alert |
| 08/29/2024 | Buy Now | — | Needham | Ami Fadia61% | — | Reiterates | → Hold | Get Alert |
| 08/19/2024 | Buy Now | 67.02% | Jefferies | Akash Tewari44% | $177 → $189 | Maintains | Buy | Get Alert |
| 08/07/2024 | Buy Now | 59.95% | JP Morgan | Anupam Rama59% | $173 → $181 | Maintains | Overweight | Get Alert |
| 08/05/2024 | Buy Now | 67.9% | HC Wainwright & Co. | Andrew Fein56% | $160 → $190 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 26.37% | RBC Capital | Brian Abrahams52% | $136 → $143 | Maintains | Sector Perform | Get Alert |
| 08/02/2024 | Buy Now | 59.07% | Guggenheim | Yatin Suneja48% | $170 → $180 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 39.63% | Citigroup | David Hoang41% | $150 → $158 | Maintains | Neutral | Get Alert |
| 08/02/2024 | Buy Now | 93.53% | Oppenheimer | Jay Olson62% | $216 → $219 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | 59.07% | Barclays | Carter Gould58% | $169 → $180 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 59.07% | Baird | Brian Skorney57% | $157 → $180 | Maintains | Outperform | Get Alert |
| 08/01/2024 | Buy Now | — | Needham | Ami Fadia61% | — | Reiterates | → Hold | Get Alert |
| 07/25/2024 | Buy Now | 36.97% | Cantor Fitzgerald | Charles Duncan72% | $155 → $155 | Reiterates | Overweight → Overweight | Get Alert |
| 07/25/2024 | Buy Now | — | Needham | Ami Fadia61% | — | Reiterates | → Hold | Get Alert |
| 07/12/2024 | Buy Now | 50.23% | Morgan Stanley | Jeffrey Hung55% | $160 → $170 | Maintains | Overweight | Get Alert |
| 07/10/2024 | Buy Now | 52.88% | JP Morgan | Anupam Rama59% | $169 → $173 | Maintains | Overweight | Get Alert |
| 06/12/2024 | Buy Now | 41.39% | Morgan Stanley | Jeffrey Hung55% | $160 → $160 | Maintains | Overweight | Get Alert |
| 05/29/2024 | Buy Now | 34.32% | Wedbush | Laura Chico47% | $152 → $152 | Reiterates | Outperform → Outperform | Get Alert |
| 05/28/2024 | Buy Now | 70.55% | UBS | Ashwani Verma47% | $174 → $193 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 54.65% | Evercore ISI Group | Cory Kasimov70% | → $175 | Initiates | → Outperform | Get Alert |
| 05/03/2024 | Buy Now | 32.56% | Citigroup | David Hoang41% | $140 → $150 | Maintains | Neutral | Get Alert |
| 05/02/2024 | Buy Now | 44.93% | Canaccord Genuity | Sumant Kulkarni43% | $154 → $164 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | 50.23% | Guggenheim | Yatin Suneja48% | $164 → $170 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | 49.35% | Barclays | Carter Gould58% | $150 → $169 | Maintains | Overweight | Get Alert |
| 05/02/2024 | Buy Now | 21.95% | BMO Capital | Evan Seigerman64% | $129 → $138 | Maintains | Market Perform | Get Alert |
| 05/02/2024 | Buy Now | 90.88% | Oppenheimer | Jay Olson62% | $200 → $216 | Maintains | Outperform | Get Alert |
| 05/02/2024 | Buy Now | 41.39% | HC Wainwright & Co. | Andrew Fein56% | $150 → $160 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | — | Needham | Ami Fadia61% | — | Reiterates | → Hold | Get Alert |
| 05/01/2024 | Buy Now | — | Needham | Ami Fadia61% | — | Reiterates | → Hold | Get Alert |
| 04/24/2024 | Buy Now | 32.56% | HC Wainwright & Co. | Andrew Fein56% | $150 → $150 | Reiterates | Buy → Buy | Get Alert |
| 04/24/2024 | Buy Now | 50.23% | Wells Fargo | Mohit Bansal72% | $140 → $170 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 04/24/2024 | Buy Now | 76.74% | Oppenheimer | Jay Olson62% | $200 → $200 | Maintains | Outperform | Get Alert |
| 04/23/2024 | Buy Now | — | Needham | Ami Fadia61% | — | Reiterates | → Hold | Get Alert |
| 04/17/2024 | Buy Now | 29.9% | Wedbush | Laura Chico47% | $147 → $147 | Reiterates | Outperform → Outperform | Get Alert |
| 04/10/2024 | Buy Now | 36.97% | Cantor Fitzgerald | Charles Duncan72% | → $155 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | Buy Now | 39.63% | JP Morgan | Anupam Rama59% | $148 → $158 | Maintains | Overweight | Get Alert |
| 03/13/2024 | Buy Now | 76.74% | Oppenheimer | Jay Olson62% | $170 → $200 | Maintains | Outperform | Get Alert |
| 02/23/2024 | Buy Now | 30.79% | JP Morgan | Anupam Rama59% | $154 → $148 | Maintains | Overweight | Get Alert |
| 02/08/2024 | Buy Now | 23.72% | Citigroup | David Hoang41% | $141 → $140 | Maintains | Neutral | Get Alert |
| 02/08/2024 | Buy Now | 23.72% | Mizuho | Uy Ear64% | $116 → $140 | Maintains | Neutral | Get Alert |
| 02/08/2024 | Buy Now | 23.72% | Wells Fargo | Mohit Bansal72% | $127 → $140 | Maintains | Equal-Weight | Get Alert |
| 01/25/2024 | Buy Now | 35.21% | Goldman Sachs | Chris Shibutani56% | $134 → $153 | Maintains | Buy | Get Alert |
| 01/23/2024 | Buy Now | 32.56% | Barclays | Carter Gould58% | $145 → $150 | Maintains | Overweight | Get Alert |
| 12/18/2023 | Buy Now | 27.25% | Stifel | Paul Matteis43% | $141 → $144 | Maintains | Buy | Get Alert |
| 12/13/2023 | Buy Now | 12.23% | Wells Fargo | Mohit Bansal72% | $110 → $127 | Maintains | Equal-Weight | Get Alert |
| 12/13/2023 | Buy Now | 12.23% | Citigroup | David Hoang41% | → $127 | Initiates | → Neutral | Get Alert |
| 12/12/2023 | Buy Now | 20.18% | Deutsche Bank | Neena Bitritto-Garg58% | → $136 | Initiates | → Buy | Get Alert |
| 12/07/2023 | Buy Now | 32.56% | Canaccord Genuity | Sumant Kulkarni43% | → $150 | Reiterates | Buy → Buy | Get Alert |
| 11/10/2023 | Buy Now | -11.63% | BMO Capital | Evan Seigerman64% | $111 → $100 | Maintains | Market Perform | Get Alert |
| 11/10/2023 | Buy Now | 6.93% | RBC Capital | Brian Abrahams52% | $128 → $121 | Maintains | Sector Perform | Get Alert |
| 11/10/2023 | Buy Now | 0.74% | Mizuho | Uy Ear64% | $116 → $114 | Maintains | Neutral | Get Alert |
| 11/03/2023 | Buy Now | 2.51% | Mizuho | Uy Ear64% | $113 → $116 | Maintains | Neutral | Get Alert |
| 11/01/2023 | Buy Now | 13.11% | RBC Capital | Brian Abrahams52% | $123 → $128 | Maintains | Sector Perform | Get Alert |
| 11/01/2023 | Buy Now | -11.63% | Piper Sandler | David Amsellem71% | $95 → $100 | Maintains | Neutral | Get Alert |
| 11/01/2023 | Buy Now | 28.14% | Raymond James | Danielle Brill43% | $135 → $145 | Maintains | Outperform | Get Alert |
| 10/24/2023 | Buy Now | — | Cantor Fitzgerald | Charles Duncan72% | — | Assumes | → Overweight | Get Alert |
| 10/06/2023 | Buy Now | 45.81% | Oppenheimer | Jay Olson62% | $160 → $165 | Maintains | Outperform | Get Alert |
| 10/06/2023 | Buy Now | 32.56% | HC Wainwright & Co. | Andrew Fein56% | $146 → $150 | Maintains | Buy | Get Alert |
| 09/13/2023 | Buy Now | 27.25% | Canaccord Genuity | Sumant Kulkarni43% | $132 → $144 | Maintains | Buy | Get Alert |
| 09/13/2023 | Buy Now | -0.14% | Mizuho | Uy Ear64% | → $113 | Reiterates | Neutral → Neutral | Get Alert |
| 09/13/2023 | Buy Now | 21.07% | Wedbush | Laura Chico47% | $120 → $137 | Maintains | Outperform | Get Alert |
| 09/13/2023 | Buy Now | 18.42% | JP Morgan | Anupam Rama59% | $133 → $134 | Maintains | Overweight | Get Alert |
| 09/13/2023 | Buy Now | 20.18% | Cantor Fitzgerald | Charles Duncan72% | → $136 | Reiterates | Overweight → Overweight | Get Alert |
| 09/13/2023 | Buy Now | -1.91% | BMO Capital | Evan Seigerman64% | $100 → $111 | Maintains | Market Perform | Get Alert |
| 09/13/2023 | Buy Now | 29.02% | HC Wainwright & Co. | Andrew Fein56% | → $146 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Neurocrine Biosciences (NBIX) stock?
The latest price target for Neurocrine Biosciences (NASDAQ:NBIX) was reported by JP Morgan on March 26, 2025. The analyst firm set a price target for $184.00 expecting NBIX to rise to within 12 months (a possible 62.60% upside). 70 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Neurocrine Biosciences (NBIX)?
The latest analyst rating for Neurocrine Biosciences (NASDAQ:NBIX) was provided by JP Morgan, and Neurocrine Biosciences maintained their overweight rating.
When was the last upgrade for Neurocrine Biosciences (NBIX)?
The last upgrade for Neurocrine Biosciences Inc happened on August 29, 2024 when Piper Sandler raised their price target to $159. Piper Sandler previously had a neutral for Neurocrine Biosciences Inc.
When was the last downgrade for Neurocrine Biosciences (NBIX)?
There is no last downgrade for Neurocrine Biosciences.
When is the next analyst rating going to be posted or updated for Neurocrine Biosciences (NBIX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurocrine Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurocrine Biosciences was filed on March 26, 2025 so you should expect the next rating to be made available sometime around March 26, 2026.
Is the Analyst Rating Neurocrine Biosciences (NBIX) correct?
While ratings are subjective and will change, the latest Neurocrine Biosciences (NBIX) rating was a maintained with a price target of $183.00 to $184.00. The current price Neurocrine Biosciences (NBIX) is trading at is $113.16, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.